Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

(2015) Alan D. Feiger et al.   CNS SPECTRUMS

Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder

(2013) Gerald Gartlehner et al.   ANNALS OF INTERNAL MEDICINE

Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol

(2012) Tina Marie Myers Oakes et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Short-Term Dynamic Psychotherapy Versus Pharmacotherapy for Major Depressive Disorder

(2011) Jacques P. Barber et al.   JOURNAL OF CLINICAL PSYCHIATRY

Symptomatic and Functional Improvement in Employed Depressed Patients

(2011) Boadie W. Dunlop et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Paroxetine controlled-release formulation in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled study in Japan and Korea

(2011) Teruhiko Higuchi et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

National Patterns in Antidepressant Medication Treatment

(2009) Mark Olfson et al.   ARCHIVES OF GENERAL PSYCHIATRY

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

(2009) Karen A. Tourian et al.   CLINICAL THERAPEUTICS

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

(2009) Patrice Boyer et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm

(2009) Ulrich Hegerl et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants

(2009) Howard G. Birnbaum et al.   PHARMACOECONOMICS

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants

(2008) Eric Wu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons

(2008) Jeroen P. Jansen et al.   VALUE IN HEALTH

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

(2006) Pei-xian Mao et al.   DEPRESSION AND ANXIETY